These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 28944966

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Using a dermal skin substitute in the treatment of chronic wounds secondary to recessive dystrophic epidermolysis bullosa: a case series.
    Sibbald RG, Zuker R, Coutts P, Coelho S, Williamson D, Queen D.
    Ostomy Wound Manage; 2005 Nov; 51(11):22-46. PubMed ID: 16319445
    [Abstract] [Full Text] [Related]

  • 7. Management of esophageal strictures in children with recessive dystrophic epidermolysis bullosa.
    Castillo RO, Davies YK, Lin YC, Garcia M, Young H.
    J Pediatr Gastroenterol Nutr; 2002 May; 34(5):535-41. PubMed ID: 12050581
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Use of a keratin-based hydrogel in the management of recessive dystrophic epidermolysis bullosa.
    Than MP, Smith RA, Cassidy S, Kelly R, Marsh C, Maderal A, Kirsner RS.
    J Dermatolog Treat; 2013 Aug; 24(4):290-1. PubMed ID: 22208480
    [Abstract] [Full Text] [Related]

  • 12. Lack of efficacy of phenytoin in recessive dystrophic epidermolysis bullosa. Epidermolysis Bullosa Study Group.
    Caldwell-Brown D, Stern RS, Lin AN, Carter DM.
    N Engl J Med; 1992 Jul 16; 327(3):163-7. PubMed ID: 1608407
    [Abstract] [Full Text] [Related]

  • 13. Use of a keratin-based wound dressing in the management of wounds in a patient with recessive dystrophic epidermolysis bullosa.
    Kirsner RS, Cassidy S, Marsh C, Vivas A, Kelly RJ.
    Adv Skin Wound Care; 2012 Sep 16; 25(9):400-3. PubMed ID: 22914035
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa.
    Tang JY, Marinkovich MP, Lucas E, Gorell E, Chiou A, Lu Y, Gillon J, Patel D, Rudin D.
    Orphanet J Rare Dis; 2021 Apr 13; 16(1):175. PubMed ID: 33849616
    [Abstract] [Full Text] [Related]

  • 18. Losartan as disease modulating therapy for recessive dystrophic epidermolysis bullosa.
    Inamadar AC.
    Dermatol Ther; 2020 Nov 13; 33(6):e14279. PubMed ID: 32888385
    [Abstract] [Full Text] [Related]

  • 19. Epidermolysis bullosa pruriginosa: A rare entity which responded well to thalidomide.
    Rani S, Gupta A, Bhardwaj M.
    Dermatol Ther; 2019 Sep 13; 32(5):e13035. PubMed ID: 31355515
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.